secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-10-13T13:23:00+00:00
Accession:  0001493152-26-046755
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

bioAffinity to present CHEST 2026 data on sputum tests for asthma and COPD lung inflammation
--------------------------------------------------------------------------------

- bioAffinity will present poster 3071 at CHEST 2026 on Oct. 20 in Phoenix on sputum-based tests measuring lung inflammation in asthma and COPD.
- Research measured targets TSLP, CRLF2, IL4-Rα (CD124) and IL-5, linked to drugs tezepelumab, verkitug, dupilumab and mepolizumab.
- Sputum samples came from people with asthma, smokers with/without COPD, a smoker with both COPD and asthma, and healthy individuals; flow cytometry, ELISA and machine learning were used.
- CyPath Lung, marketed as an LDT, showed 92% sensitivity, 87% specificity, 88% accuracy and 99% NPV for lung cancer in high-risk patients with nodules under 20 mm.
- Global asthma therapeutics market was about $29.7 billion in 2025 and is projected to reach $47.6 billion by 2034.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046755/0001493152-26-046755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226046755/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-046755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer